Lab Anim Res.  2010 Sep;26(3):257-263.

Antibacterial Activity of Sanguisorba officinalis against Helicobacter pylori

Affiliations
  • 1Center for Animal Resources Development, Wonkwang University, Iksan, Korea.
  • 2Huvet Co. Ltd, Iksan, Korea.
  • 3Korea DNA Valley Co. Ltd, Iksan, Korea.
  • 4College of Pharmacy, Wonkwang University, Iksan, Korea.
  • 5Zoonosis Research Center, Wonkwang University, Iksan, Korea.
  • 6Institute of Animal Experiment & Efficacy Evaluattion, Wonkwang University, Iksan, Korea.

Abstract

In this study, a medicinal herbal plant, Sanguisorba officinalis, was examined and screened for anti-Helicobacter pylori (H. pylori) activity. Seventy percent ethanol was used for herbal extraction. For anti-H. pylori activity screening, inhibitory zone tests as an in vitro assay and in vivo study using a Mongolian gerbil (Meriones unguiculatus) model were performed. Also, the safety of herbal compounds was evaluated by animal study. As a result of inhibitory zone test, Sanguisorba officinalis extract demonstrated strong anti-H. pylori activities. Also, as results of in vivo animal studies, Sanguisorba officinalis extract demonstrated strong therapeutic effects against H. pylori infection according to the criteria of histological examination and rapid urease test. As results of the safety study, after 28 days treatment of the Sanguisorba officinalis extract, the animals were not detected any grossly and histological changes. These results demonstrate that it can be successfully cured against H. pylori infection and protected from H. pylori-induced pathology with Sanguisorba officinalis extract. It could be a promising candidate herb treatment for patients with gastric complaints including gastric ulcer caused by H. pylori.

Keyword

Sanguisorba officinalis; Helicobacter pylori; antibacterial activity; herb; therapy

MeSH Terms

Animals
Ethanol
Gerbillinae
Helicobacter
Helicobacter pylori
Humans
Mass Screening
Plants
Plants, Medicinal
Sanguisorba
Stomach Ulcer
Urease
Ethanol
Urease

Figure

  • Figure 1. Results of polymerase chin reaction in the study of anti-H. pylori activity with Sanguisorba officinalis extract. M: 100 bp marker, P: DNA from H. pylori ATCC 43504, N: negative control, 1~2: Group I (H. pylori+Sanguisorba officinalis), 3~6: Group II (H. pylori + phosphate-buffered saline).


Reference

An B. J.., Lee J. T.., Lee S. A.., Kwak J. H.., Park J. M.., Lee J. Y.., Son J. H.2004. Antioxidant effects and application as natural ingredients of Korean Sanguisorbae officinalis L. J. Korean Soc. Appl. Biol. Chem. 47(2):244–250.
Ahn Y. O.., Park B. J.., Yoo K. Y.., Kim N. K.., Heo D. S.., Lee J. K.., Ahn H. S.., Kang D. H.., Kim H.., Lee M.S.., Park T.S.1991. Incidence estimation of stomach cancer among Koreans. J. Kor. Med. Sci. 6:7–14.
Article
Bastow K. F.., Bori I. D.., Fukushima Y.., Kashiwada Y.., Tanaka T.., Nonaka G.., Nishioka I.., Lee K.-H.1993. Inhibition of DNA Topoisomerases by sanguiin H-6, a cytotoxic dimeric ellagitannin from Sanguisorba officinalis. Planta Med. 59:240–245.
Han D.S.2007. Treatment of H. pylori infection and current status of vaccine development. Hanyang Med. Rev. 27:81–95.
Hansson L. E.., Nyren O.., Hsing A. W.., Bergstrom R.., Josefsson S.., Chow W. H.., Fraumeni J. F.., Adami H.O.1996. The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N. Engl. J. Med. 355:242–249.
Article
Harris A.1997. Treatment of Helicobacter pylori. Drugs Today. 33:59–66.
Honda S.., Fujioka T.., Tokieda M.., Satoh R.., Nishizono A.., Nasu M.1998. Development of Helicobacter pylori induced-gastric carcinoma in Mongolian gerbils. Cancer Res. 58:4255–4259.
Jung T. S.., Kang S. C.., Choi Y. J.., Jeon B. S.., Park J. W.., Jung S. A.., Song J. Y.., Choi S. H.., Park S. G.., Choe M. Y.., Lee B. S.., Byun E. Y.., Baik S. C.., Lee W. K.., Cho M. J.., Youn H. S.., Ko G. H.., Rhee K. H.2000. Two-dimensional gel electrophoresis of Helicobacter pylori for proteomic analysis. J. Korean Soc. Microbiol. 35:97–108.
Kim B. W.., Choi M. G.., Choi H.., Moon S. B.., Kim B. K.., Chae H. S.., Kim J. K.., Chung I. S.., Chung K. W.., Sun H. S.., Park D.H.1999. Pooled analysis of antibiotic therapy for Helicobacter pylori eradication in Korea. Korean J. Gastroenterol. 34:42–49.
Kim J. M.2007. Antibiotic resistance in Helicobacter pylori. Hanyang Med. Rev. 27:80–95.
Kim J. M.., Kim J. S.., Jung H. C.., Kim N.., Kim Y. J.., Song I. S.2004. Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea. Antimicrob. Agents Chemother. 48:4843–4847.
Kim S. H.., Kim O. J.2004. Application of consensus polymerase chain reaction for monitoring of Helicobacter species. Lab. Animal. Res. 20:316–320.
Koehn F. E.., Carter G. T.2005. The evolving role of natural products in drug discovery. Nat. Rev. Drug Discov. 4:206–220.
Article
Lee J.., Kim S. M.., Im E. H.., Choi Y. W.., Kim Y. M.., Kim P. S.., Lee J. H.2005. The prevalence of antimicrobial resistance in Helicobacter pylori isolated in Daejeon. Korean J. Clin. Microbiol. 8:47–50.
Lee J. Y.., Kim W.., Gawk G. Y.., Park S. C.., Ye B. D.., Lee S. H.., Kim S. G.., Kim J. S.., Jun H. C.., Song I. S.2002. Reinfection rate and clinical manifestation of Helicobacter pylori-positive peptic ulcer disease after triple therapy containing clarithromycin. Korean J. Gastrornterol. 39:93–100.
Lim T. H.., Lee J. M.., Cha B. J.2002. Antifungal activity and identification of an Actinomycetes straun isolated from mummified peaches. Kor. J. Appl. Microbiol. Biotechnol. 28:161–166.
Marshall B. J.., Warren J. R.1984. Unidentified curved bacilli in the stomach of patients with gastric and peptic ulceration. Lancet. 1:1311–1315.
Nguyen T.T.., Cho S.O.., Ban J.Y.., Kim J.Y.., Ju H.S.., Koh S.B.., Song K.S.., Seong Y.H.2008. Neuroprotective effect of Sanguisorbae radix against oxidative stress-induced brain damage: in vitro and in vivo. Biol. Pharm. Bull. 31(11):2028–2035.
Article
Park H. J.., Kim J. W.., Lee J. H.., Shin J. H.., Yu K. A.2000. Detection of clarithromycin resistant Helicobacter pylori by polymerase chain reaction. Korean J. Gastroenterol. 47:459–461.
Park K.H.., Koh D.., Kim K.., Park J.., Lim Y.2004. Antiallergic activity of a disaccharide isolated from Sanguisorba officinalis. Phytother. Res. 18(8):658–662.
Reher G.., Budesinsky M.1992. Triterpenoids from plants of the anguissorbeae. Phytochemistry. 31:3909–3914.
Shim S. G.., Kim J. J.., Kim Y. H.., Sung I. K.., Son H. J.., Lee K. T.., Rhee P. L.., Koh K. C.., Paik S. W.., Rhee J. C.., Choi K. W.., Kim C. S.., Choi M. S.., Ryu K. H.., Lee, H. Y. Heo J. S.., Noh J.H.2000. One-week triple therapy for Helicobacter pylori a prospective, randomized study. Korean J. Gastroenterol. 35:16–22.
Tanaka T.., Nonaka G.., Nishioka I.1983. 7-O-Galloyl-(+)catechin and 3-O-galloylprocyanidin B-3 from Sanguisorba officinalis. Phytochemistry. 22:2575–2578.
Article
Velazquez M.., Feirtag J. M.1999. Helicobacter pylori: characteristics, pathogenicity, detection methods and mode of transmission implicating foods and water. Int. J. Microbiol. 53:95–104.
53, 95-104. Wouden E.., Thijs J.., Zwet A.., Sluiter W.., Kleibeuker J.1999. The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a metaanalysis. Am. J. Gastroenterol. 94:1751–1759.
Yam M.F.., Ang L.F.., Salman I.M.., Ameer O.Z.., Lim V.., Ong L.M.., Ahmad M.., Asmawil M.Z.., Basir R.2009. Orthosiphon stamineus leaf extract protects against ethanol-induced gastropathy in rats. J. Med. Food. 12(5):1089–1097.
Article
Yokozawa T.., Chen C. P.., Tanaka T.., Kitani K.2000. A study on the nitric oxide production-suppressing activity of Sanguisorbae Radix components. Biol. Pharm. Bull. 23:717–722.
Article
Full Text Links
  • LAR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr